Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Core Insights - Inhibikase Therapeutics has completed enrollment in the Phase 2 '201' trial for risvodetinib, a selective c-Abl inhibitor, aimed at treating untreated Parkinson's disease, with results expected in Q4 2024 [1][2] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for Parkinson's disease and related disorders, with its lead program risvodetinib targeting the treatment of Parkinson's disease and other conditions related to Abelson Tyrosine Kinases [3] - The company is headquartered in Atlanta, Georgia, with additional offices in Lexington, Massachusetts [3] Trial Details - The 201 Trial is a 12-week, randomized, double-blind, multi-center, placebo-controlled clinical trial evaluating three doses of risvodetinib in 120 participants across 32 U.S. sites, assessing safety, tolerability, and efficacy [2] - As of June 17, 2024, 69 participants have completed the dosing period, with 32 mild and 5 moderate adverse events reported, and four participants withdrew from the trial [2]